Exelixis Inc
NASDAQ:EXEL
Exelixis Inc
Gross Profit
Exelixis Inc
Gross Profit Peer Comparison
Competitive Gross Profit Analysis
Latest Figures & CAGR of Competitors
Company | Gross Profit | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
Exelixis Inc
NASDAQ:EXEL
|
Gross Profit
$1.8B
|
CAGR 3-Years
21%
|
CAGR 5-Years
16%
|
CAGR 10-Years
53%
|
|
Abbvie Inc
NYSE:ABBV
|
Gross Profit
$36.1B
|
CAGR 3-Years
3%
|
CAGR 5-Years
7%
|
CAGR 10-Years
10%
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Gross Profit
$20.8B
|
CAGR 3-Years
0%
|
CAGR 5-Years
4%
|
CAGR 10-Years
7%
|
|
Amgen Inc
NASDAQ:AMGN
|
Gross Profit
$19.6B
|
CAGR 3-Years
1%
|
CAGR 5-Years
0%
|
CAGR 10-Years
3%
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Gross Profit
$8.8B
|
CAGR 3-Years
16%
|
CAGR 5-Years
26%
|
CAGR 10-Years
26%
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Gross Profit
$11.3B
|
CAGR 3-Years
12%
|
CAGR 5-Years
13%
|
CAGR 10-Years
18%
|
See Also
What is Exelixis Inc's Gross Profit?
Gross Profit
1.8B
USD
Based on the financial report for Mar 29, 2024, Exelixis Inc's Gross Profit amounts to 1.8B USD.
What is Exelixis Inc's Gross Profit growth rate?
Gross Profit CAGR 10Y
53%
Over the last year, the Gross Profit growth was 10%. The average annual Gross Profit growth rates for Exelixis Inc have been 21% over the past three years , 16% over the past five years , and 53% over the past ten years .